Targeting core nodes such as ChREBP, ALCAT1 and Drp1, combined with natural products to intervene in the cleavage-fusion imbalance, is expected to provide a new strategy to slow down the progression of DKD. This evidence concerns the gene MLXIPL and diabetic kidney disease.